4F2hc-silencing impairs tumorigenicity of HeLa cells via modulation of galectin-3 and β-catenin signaling, and MMP-2 expression

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 9, 2013, Pages 2045-2056

  Santiago Gómez, Angélica ^a   Barrasa, Juan I ^a   Olmo, Nieves ^a   Lecona, Emilio ^a   Burghardt, Hans ^b   Palacín, Manuel ^b   Lizarbe, Ma Antonia ^a   Turnay, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

Author keywords

CD98hc; Galectin 3; Hela cells; Integrin signaling; Matrix metalloproteinases; Catenin

Indexed keywords

4F2HC PROTEIN; BETA CATENIN; GALECTIN 3; GELATINASE A; GLYCOPROTEIN; UNCLASSIFIED DRUG; BETA1 INTEGRIN; CD147 ANTIGEN; FOCAL ADHESION KINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; BSG PROTEIN, HUMAN; CD98 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MMP2 PROTEIN, HUMAN; PROTEASOME; SLC3A2 PROTEIN, HUMAN;

ARTICLE; CARCINOGENICITY; CELL MOTILITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; INTRACELLULAR SIGNALING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTIGENS, CD147; ANTIGENS, CD29; ANTIGENS, CD98 HEAVY CHAIN; BETA CATENIN; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GALECTIN 3; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSPLANTATION, HETEROLOGOUS;

EID: 84883068015     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.04.017     Document Type: Article

References (67)

1. B.F. Haynes, Human T lymphocyte antigens as defined by monoclonal antibodies, Immunol. Rev. 57 (1981) 127-161.
2. J. Chillarón, R. Roca, A. Valencia, A. Zorzano, M. Palacín, Heteromeric amino acid transporters: biochemistry, genetics, and physiology, Am. J. Physiol. Renal Physiol. 281 (2001) F995-F1018.
3. P. Nicklin, P. Bergman, B. Zhang, E. Triantafellow, H. Wang, B. Nyfeler, H. Yang, M. Hild, C. Kung, C. Wilson, V.E. Myer, J.P. MacKeigan, J.A. Porter, Y.K. Wang, L.C. Cantley, P.M. Finan, L.O. Murphy, Bidirectional transport of amino acids regulates mTOR and autophagy, Cell 136 (2009) 521-534.
4. C.A. Fenczik, T. Sethi, J.W. Ramos, P.E. Hughes, M.H. Ginsberg, Complementation of dominant suppression implicates CD98 in integrin activation, Nature 390 (1997) 81-85.
5. C.C. Féral, N. Nishiya, C.A. Fenczik, H. Stuhlmann, M. Slepak, M.H. Ginsberg, CD98hc (SLC3A2) mediates integrin signaling, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 355-360.
6. G.W. Prager, C.C. Féral, C. Kim, J. Han, M.H. Ginsberg, CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling, J. Biol. Chem. 282 (2007) 24477-24484.
7. K. Hara, H. Kudoh, T. Enomoto, Y. Hashimoto, T. Masuko, Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98, Biochem. Biophys. Res. Commun. 262 (1999) 720-725.
8. N. Bulus, C. Féral, A. Pozzi, R. Zent, CD98 increases renal epithelial cell proliferation by activating MAPKs, PLoS One 7 (2012) e40026.
9. H.T. Nguyen, G. Dalmasso, Y. Yan, H. Laroui,M. Charania, S. Ingersoll, S. Ayyadurai, Y. Zhang, S. Sitaraman, D. Merlin, Intestinal epithelial cell-specific CD98 expression regulates tumorigenesis in Apc(Min/+) mice, Lab. Invest. 92 (2012) 1203-1212.
10. P. Fogelstrand, C.C. Feral, R. Zargham, M.H. Ginsberg, Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2), J. Exp. Med. 206 (2009) 2397-2406.
11. H. Yang, W. Zou, Y. Li, B. Chen, X. Xin, Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells, Cancer Biol. Ther. 6 (2007) 942-947.
12. S. Esseghir, J.S. Reis-Filho, A. Kennedy, M. James, M.J. O'Hare, R. Jeffery, R. Poulsom, C.M. Isacke, Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts, J. Pathol. 210 (2006) 420-430.
13. M. Furuya, J. Horiguchi, H. Nakajima, Y. Kanai, T. Oyama, Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis, Cancer Sci. 103 (2012) 382-389.
14. K. Kaira, Y. Ohde,M. Endo, K. Nakagawa, T. Okumura, T. Takahashi, H.Murakami, A. Tsuya, Y. Nakamura, T. Naito, H. Kondo, T. Nakajima, N. Yamamoto, Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors, Oncol. Rep. 26 (2011) 931-937.
15. K. Kaira, T. Takahashi, M. Abe, H. Akamatsu, K. Nakagawa, Y. Ohde, T. Okumura, H. Murakami, A. Tsuya, Y. Nakamura, T. Naito, H. Kondo, T. Nakajima, M. Endo, N. Yamamoto, CD98 expression is associated with the grade of malignancy in thymic epithelial tumors, Oncol. Rep. 24 (2010) 861-867.
16. D. Xu, M.E. Hemler, Metabolic activation-related CD147-CD98 complex, Mol. Cell. Proteomics 4 (2005) 1061-1071.
17. P. Kirk, M.C. Wilson, C. Heddle, M.H. Brown, A.N. Barclay, A.P. Halestrap, CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression, EMBO J. 19 (2000) 3896-3904.
18. F. Berditchevski, S. Chang, J. Bodorova, M.E. Hemler, Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6, J. Biol. Chem. 272 (1997) 29174-29180.
19. W. Tang, M.E. Hemler, Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering, J. Biol. Chem. 279 (2004) 11112-11118.
20. B.P. Toole, Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function, Curr. Top. Dev. Biol. 54 (2003) 371-389.
21. S. Caudroy, M. Polette, B. Nawrocki-Raby, J. Cao, B.P. Toole, S. Zucker, P. Birembaut, EMMPRIN-mediated MMP regulation in tumor and endothelial cells, Clin. Exp. Metastasis 19 (2002) 697-702.
22. S. Zucker, M. Hymowitz, E.E. Rollo, R. Mann, C.E. Conner, J. Cao, H.D. Foda, D.C. Tompkins, B.P. Toole, Tumorigenic potential of extracellularmatrixmetalloproteinase inducer, Am. J. Pathol. 158 (2001) 1921-1928.
23. P. Vihinen, V.M. Kahari, Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets, Int. J. Cancer 99 (2002) 157-166.
24. I. Navarro-Lérida, A. Álvarez-Barrientos, F. Gavilanes, I. Rodríguez-Crespo, Distance-dependent cellular palmitoylation of de-novo-designed sequences and their translocation to plasma membrane subdomains, J. Cell Sci. 115 (2002) 3119-3130.
25. J.I. Barrasa, N. Olmo, A. Santiago-Gómez, E. Lecona, P. Anglard, J. Turnay, M.A. Lizarbe, Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells, Biochim. Biophys. Acta 1823 (2012) 570-581.
26. E. Lecona, J.I. Barrasa, N. Olmo, B. Llorente, J. Turnay, M.A. Lizarbe, Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase, Mol. Cell. Biol. 28 (2008) 4665-4674.
27. A. Guzmán-Aránguez, N. Olmo, J. Turnay, E. Lecona, P. Pérez-Ramos, I. López de Silanes, M.A. Lizarbe, Differentiation of human colon adenocarcinoma cells alters the expression and intracellular localization of annexins A1, A2, and A5, J. Cell. Biochem. 94 (2005) 178-193.
28. P. Calero, E. Jorge-Herrero, J. Turnay, N. Olmo, I. López de Silanes, M.A. Lizarbe, M.M. Maestro, B. Arenaz, J.L. Castillo-Olivares, Gelatinases in soft tissue biomaterials. Analysis of different crosslinking agents, Biomaterials 23 (2002) 3473-3478.
29. C. Gialeli, A.D. Theocharis, N.K. Karamanos, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J. 278 (2011) 16-27.
30. C. Klockenbusch, J. Kast, Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1, J. Biomed. Biotechnol. 2010 (2010) 927585.
31. J.I. Barrasa, N. Olmo, P. Pérez-Ramos, A. Santiago-Gómez, E. Lecona, J. Turnay, M.A. Lizarbe, Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells, Apoptosis 16 (2011) 1054-1067.
32. S. Ovalle, M.D. Gutiérrez-López, N. Olmo, J. Turnay, M.A. Lizarbe, P. Majano, F. Molina-Jiménez, M. López-Cabrera, M. Yáñez-Mo, F. Sánchez-Madrid, C. Cabañas, The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells, Int. J. Cancer 121 (2007) 2140-2152.
33. T. López-Conejo, N. Olmo, J. Turnay, J. Navarro, A. Lizarbe, Characterization of tumorigenic sub-lines from a poorly tumorigenic human colon-adenocarcinoma cell line, Int. J. Cancer 67 (1996) 668-675.
34. G. Moreno-Bueno, H. Peinado, P. Molina, D. Olmeda, E. Cubillo, V. Santos, J. Palacios, F. Portillo, A. Cano, The morphological and molecular features of the epithelial-to-mesenchymal transition, Nat. Protoc. 4 (2009) 1591-1613.
35. F. Faul, E. Erdfelder, A. Buchner, A.G. Lang, Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses, Behav. Res. Methods 41 (2009) 1149-1160.
36. T.V. Kolesnikova, B.A. Mannion, F. Berditchevski, M.E. Hemler, Beta1 integrins show specific association with CD98 protein in low density membranes, BMC Biochem. 2 (2001) 10.
37. M.W. Roomi, J.C. Monterrey, T. Kalinovsky, M. Rath, A. Niedzwiecki, In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors, Oncol. Rep. 23 (2010) 605-614.
38. N. Intasai, K. Tragoolpua, P. Pingmuang, P. Khunkaewla, S. Moonsom, W. Kasinrerk, A. Lieber, C. Tayapiwatana, Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9, Immunobiology 214 (2009) 401-421.
39. M. Kabir-Salmani, M.N. Fukuda, M. Kanai-Azuma, N. Ahmed, S. Shiokawa, Y. Akimoto, K. Sakai, S. Nagamori, Y. Kanai, K. Sugihara, M. Iwashita, The membrane-spanning domain of CD98 heavy chain promotes alpha(v)beta3 integrin signals in human extravillous trophoblasts, Mol. Endocrinol. 22 (2008) 707-715.
40. A. Khwaja, P. Rodriguez-Viciana, S. Wennstrom, P.H. Warne, J. Downward, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, EMBO J. 16 (1997) 2783-2793.
41. C. Liu, Y. Li, M. Semenov, C. Han, G.H. Baeg, Y. Tan, Z. Zhang, X. Lin, X. He, Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell 108 (2002) 837-847.
42. B.P. Zhou, J.Deng,W. Xia, J. Xu, Y.M. Li,M. Gunduz,M.C.Hung, Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition, Nat. Cell Biol. 6 (2004) 931-940.
43. J.M. McInerney, J.R. Nawrocki, C.H. Lowrey, Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine, Gene Ther. 7 (2000) 653-663.
44. H.P. Mok, S. Javed, A. Lever, Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority, Gene Ther. 14 (2007) 741-751.
45. J. Cantor, C.D. Browne, R. Ruppert, C.C. Feral, R. Fassler, R.C. Rickert, M.H. Ginsberg, CD98hc facilitates B cell proliferation and adaptive humoral immunity, Nat. Immunol. 10 (2009) 412-419.
46. J. Cantor, M. Slepak, N. Ege, J.T. Chang, M.H. Ginsberg, Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity, J. Immunol. 187 (2011) 851-860.
47. J. Jiang, Y.L. Tang, X.H. Liang, EMT: a new vision of hypoxia promoting cancer progression, Cancer Biol. Ther. 11 (2011) 714-723.
48. K. Takenaga, Angiogenic signaling aberrantly induced by tumor hypoxia, Front. Biosci. 16 (2011) 31-48.
49. K. Kaira, N. Oriuchi, T. Takahashi, K. Nakagawa, Y. Ohde, T. Okumura, H. Murakami, T. Shukuya, H. Kenmotsu, T. Naito, Y. Kanai, M. Endo, H. Kondo, T. Nakajima, N. Yamamoto, LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer, Am. J. Transl. Res. 3 (2011) 468-478.
50. U.H. Weidle, W. Scheuer, D. Eggle, S. Klostermann, H. Stockinger, Cancer-related issues of CD147, Cancer Genomics Proteomics 7 (2010) 157-169.
51. M. Takahashi, S. Suzuki, K. Ishikawa, Cyclophilin A-EMMPRIN interaction induces invasion of head and neck squamous cell carcinoma, Oncol. Rep. 27 (2012) 198-203.
52. J.Y. Cho, D.A. Fox, V. Horejsi, K. Sagawa, K.M. Skubitz, D.R. Katz, B. Chain, The functional interactions between CD98, beta1-integrins, and CD147 in the induction of U937 homotypic aggregation, Blood 98 (2001) 374-382.
53. G. Lemaitre, F. Gonnet, P. Vaigot, X. Gidrol, M.T. Martin, J. Tortajada, G. Waksman, CD98, a novel marker of transient amplifying human keratinocytes, Proteomics 5 (2005) 3637-3645.
54. A. Melchior, A. Denys, A. Deligny, J. Mazurier, F. Allain, Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases, Exp. Cell Res. 314 (2008) 616-628.
55. Q.Q. Li, W.J. Wang, G.P. Xu, X.X. Cao, J.D. Xu, Q. Chen, F. Tang, Z.D. Xu, CD147 and matrix metallo-proteinase (MMP) 2 and MMP9 expression in multidrug resistant breast cancer cells treated with P-glycoprotein substrate drugs, Zhonghua Bing Li Xue Za Zhi 36 (2007) 247-252.
56. B. Davidson, V. Givant-Horwitz, P. Lazarovici, B. Risberg, J.M. Nesland, C.G. Trope, E. Schaefer, R. Reich, Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma, Clin. Exp. Metastasis 20 (2003) 621-631.
57. T. Ludwig, Local proteolytic activity in tumor cell invasion and metastasis, Bioessays 27 (2005) 1181-1191.
58. S.D. Shapiro, Matrix metalloproteinase degradation of extracellular matrix: biological consequences, Curr. Opin. Cell Biol. 10 (1998) 602-608.
59. C. López-Otín, L.M. Matrisian, Emerging roles of proteases in tumour suppression, Nat. Rev. Cancer 7 (2007) 800-808.
60. J. Ochieng, B. Green, S. Evans, O. James, P. Warfield, Modulation of the biological functions of galectin-3 by matrix metalloproteinases, Biochim. Biophys. Acta 1379 (1998) 97-106.
61. R.Y. Yang, G.A. Rabinovich, F.T. Liu, Galectins: structure, function and therapeutic potential, Expert Rev. Mol. Med. 10 (2008) e17.
62. P. Nangia-Makker, V. Balan, A. Raz, Regulation of tumor progression by extracellular galectin-3, Cancer Microenviron. 1 (2008) 43-51.
63. P. Nangia-Makker, Y. Wang, T. Raz, L. Tait, V. Balan, V. Hogan, A. Raz, Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer, Int. J. Cancer 127 (2010) 2530-2541.
64. S. Song, N. Mazurek, C. Liu, Y. Sun, Q.Q. Ding, K. Liu, M.C. Hung, R.S. Bresalier, Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity, Cancer Res. 69 (2009) 1343-1349.
65. L. Larue, A. Bellacosa, Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways, Oncogene 24 (2005) 7443-7454.
66. J.G. Lock, J.L. Stow, Rab11 in recycling endosomes regulates the sorting and basolateral transport of E-cadherin, Mol. Biol. Cell 16 (2005) 1744-1755.
67. J.H. Zhao, Y. Luo, Y.G. Jiang, D.L. He, C.T. Wu, Knockdown of beta-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1alpha, Cancer Invest. 29 (2011) 377-382.